Received 29 May 2003/Returned for modification 7 August 2003/Accepted 13 November 2003

Size: px
Start display at page:

Download "Received 29 May 2003/Returned for modification 7 August 2003/Accepted 13 November 2003"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p Vol. 48, No /04/$ DOI: /AAC Copyright 2004, American Society for Microbiology. All Rights Reserved. Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations Kirsten L. White, 1 * James M. Chen, 1 Nicolas A. Margot, 1 Terri Wrin, 2 Christos J. Petropoulos, 2 Lisa K. Naeger, 1 S. Swaminathan, 1 and Michael D. Miller 1 Gilead Sciences, Foster City, California, 94404, 1 and ViroLogic, Inc., South San Francisco, California, Received 29 May 2003/Returned for modification 7 August 2003/Accepted 13 November 2003 Two amino acids inserted between residues 69 and 70 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are rare mutations that may develop in viruses containing multiple thymidine analog (zidovudine [AZT], stavudine)-associated mutations and that confer high-level resistance to all currently approved chain-terminating nucleoside and nucleotide RT inhibitors (NRTIs). The two known mechanisms of resistance to NRTIs are decreased incorporation and increased excision. The mechanism used by RT insertion mutants has not been described for tenofovir (TFV), a recently approved agent in this class. A patient-derived HIV-1 strain (strain FS-SSS) that contained an insertion mutation in a background of additional resistance mutations M41L, L74V, L210W, and T215Y was obtained. A second virus (strain FS) was derived from FS-SSS. In strain FS the insertion and T69S were reverted but the other resistance mutations were retained. The FS virus showed strong resistance to AZT but low-level changes in susceptibilities to other NRTIs and TFV. The FS-SSS virus showed reduced susceptibilities to all NRTIs including TFV. Steady-state kinetics demonstrated that the relative binding or incorporation of TFV was slightly decreased for FS-SSS RT compared to those for wild-type RT. However, significant ATP-mediated excision of TFV was detected for both mutant RT enzymes and followed the order FS-SSS RT > FS RT > wild-type RT. The presence of physiological concentrations of the 1 nucleotide inhibited TFV excision by the wild-type RT and slightly inhibited excision by the FS RT, whereas the level of excision by the FS-SSS RT remained high. Computer modeling suggests that the increased mobility of the 3-4 loop may contribute to the high-level and broad NRTI resistance caused by the T69 insertion mutation. Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is the target for antiretroviral drugs such as nucleoside and nucleotide RT inhibitors (NRTIs). The nucleoside analogs zidovudine (AZT), didanosine (ddi), zalcitabine (ddc), stavudine (d4t), lamivudine (3TC), emtricitabine, and abacavir and the nucleotide analog tenofovir (TFV) are metabolized by cellular enzymes to their triphosphate and diphosphate active forms, respectively. Their mechanisms of action are competitive inhibition of incorporation of natural deoxynucleoside triphosphates (dntps) into proviral DNA and subsequent termination of polymerization of the viral DNA chain upon incorporation. Although NRTIs are effective at reducing viral loads in HIV-1-infected patients, their use may lead to the development of mutations in RT that contribute to HIV-1 drug resistance. In some cases, mutations that result in resistance to many NRTIs may develop. Multi-NRTI resistance patterns fall into two classes of mutations, consisting of (i) the Q151M complex, which consists of the substitutions A62V, V75I, F77L, F116Y, and Q151M, and (ii) the insertion of two amino acids between positions 69 and 70 of RT (the 69-insertion mutation). Viruses containing the insertion mutation have reduced susceptibilities to all currently * Corresponding author. Mailing address: Gilead Sciences, 333 Lakeside Dr., Foster City, CA Phone: (650) Fax: (650) kwhite@gilead.com. approved NRTIs, including TFV, but viruses containing the Q151M mutation remain susceptible to TFV and 3TC (42, 57; K. Wolf, H. Walter, N. Beerenwinkel, W. Keulen, R. Kaiser, D. Hoffmann, T. Langauer, J. Selbig, A.-M. Vandamme, K. Korn, and B. Schmidt, Abstr. 11th Int. HIV Drug Resist. Workshop: Basic Principles Clin. Implications, abstr. 20, 2002). The 69- insertion mutation typically consists of T69S plus the insertion of SS, SG, or SA between amino acids 69 and 70 of RT in a background of multiple thymidine analog-associated mutations (TAMs; consisting of substitutions at amino acids 41, 67, 70, 210, 215, and 219 of RT) that are associated with resistance to AZT and d4t (29, 35, 54, 59). The 69-insertion mutations can occur with various NRTI treatment regimens following prolonged periods of incomplete virus suppression. They have been observed most commonly after the use of AZT followed by the use of ddi or ddc, but the exact pattern(s) of drug selection has not been determined (6, 16, 29, 59). These mutations are rare, occurring in 1% of antiretroviral agentexperienced patients [6, 22, 54, 59; S. Bloor, S. D. Kemp, K. Hertogs, T. Alcorn, and B. A. Larder, Abstr. 4th Int. Workshop HIV Drug Resist. Treatment Strategies, Antivir. Ther. 5(Suppl. 3):169, 2000]. Two mechanisms are known to contribute to decreased NRTI susceptibility (47). Mutations that alter the relative binding affinities of inhibitors over the relative binding affinities of the natural substrates can result in decreased incorpo- 992

2 VOL. 48, 2004 MECHANISMS OF HIV RT RESISTANCE 993 ration of the inhibitors. An example of resistance by this mechanism is the decreased binding of 3TC triphosphate (3TC-TP), the active metabolite of 3TC, to RT with the M184V mutation (49). Mutations that increase the levels of excision of chainterminating inhibitors following incorporation into viral DNA by pyrophosphorolysis or ATP-mediated excision also contribute to drug resistance. RT mutants containing multiple TAMs excise AZT and d4t at increased levels compared to those for wild-type RT, which is the likely mechanism of AZT and d4t resistance (1, 3, 38, 45, 46). TFV disoproxil fumarate (TDF) is an oral prodrug of TFV that has recently been licensed for use for the treatment of HIV-1 infection. TFV (9-[2-(phosphonomethoxypropyl)adenine]) is an acyclic nucleotide phosphonate analog of AMP that requires two steps of phosphorylation by cellular kinases to become the active triphosphate metabolite (TFV diphosphate [TFV-PP]). The primary mutation selected for by TFV in vitro and in vivo is K65R (32, 57). Although TFV does not select for TAMs, the presence of specific combinations of TAMs, namely, T215Y together with M41L and L210W, results in reduced susceptibility to TDF (36; M. D. Miller, N. A. Margot, and B. Lu, Program Abstr. Ninth Conf. Retrovir. Opportunistic Infect., abstr. 43, p. 68, 2002). It has previously been shown that the molecular mechanism of TFV resistance by K65R RT is the decreased ability of K65R RT to bind to or incorporate TFV-PP (16a, 57, 58). Multiple TAMs and the 69-insertion mutations, however, are known to cause resistance to other NRTIs through enhanced excision (5, 30, 31, 33, 34, 37); however, the mechanism of resistance to TFV by the 69-insertion mutant RT is unknown. The 69-insertion mutations occur in the 3-4 loop, comprised of amino acids 64 to 72 located in the fingers subdomain of HIV-1 RT (26). Molecular modeling based on crystal structures of HIV-1 RT and pre-steady-state kinetics suggests that during dntp incorporation, substantial conformational changes that affect the positions of the subdomains with respect to each other occur: part of the fingers subdomain rotates toward the palm subdomain and inward toward the primertemplate and the polymerase active site (25). The polymerization process is diagrammed in Fig. 1A and is reviewed elsewhere (53). In the first step, RT binds to the template-primer. The position of the 3 terminal nucleotide of the primer in the active site resides at either the posttranslocation priming site (P site) or the pretranslocation nucleotide-binding site (N site) (3). When the primer terminus is in the P site, the N site is unoccupied. The incoming dntp binds to the N site (step 2), followed by a rate-limiting conformational change (step 3) in which the 3-4 fingers loop of RT closes from an open to a closed position (15, 24, 28). During this process close contacts are formed between the incoming dntp and RT residues K65, R72, Y115, and Q151 (25, 26). Phosphodiester bond formation occurs in step 4 to generate pyrophosphate, which is released in step 5. The order of the mechanistic steps that follow are not well defined; however, in order for the next round of polymerization to occur, the primer must translocate such that its terminus is shifted from the N site to the P site and the fingers domain must return to the open position, in which it is primed for the next dntp to bind to it. For pyrophosphorolysis (the reverse reaction of polymerization) or ATP-mediated excision to occur, the chain-terminated primer must reside in the N site in order to be excised by pyrophosphate or ATP, respectively (51). This process is diagrammed in Fig. 1B (steps 7 to 10). The product of pyrophosphorolysis is the triphosphate form of the NRTI, and the product of ATP-mediated excision is a larger dinucleoside tetraphosphate molecule (1, 3, 38). The binding of the nucleotide complementary to the next position in the template (next nucleotide) to a translocated chain-terminated primer-template-rt complex forms a stable, dead-end complex that is resistant to excision (Fig. 1, steps 11 to 12) (39, 55). The binding of physiological concentrations of the next nucleotide has been shown to decrease the excision of some NRTIs such as d4t and dda, but not AZT (5, 33, 34, 38 40, 46). This has implications for the level of resistance observed in vivo compared to that observed in vitro, in which the dntp concentrations in cell culture are relatively high (17, 23, 56) and can mask the level of resistance by excision mechanisms. The change of threonine to serine at amino acid 69 followed by the insertion of two serine residues likely affects the interaction between the enzyme and dntp substrates and might therefore alter the nucleotide-binding specificity or phosphodiester bond formation efficiency of RT. To investigate the effects of resistance mutations on RT function and the molecular mechanisms of the altered susceptibilities of these mutants to TFV, the viral susceptibility of a patient-derived HIV-1 strain containing multiple NRTI resistance mutations plus the 69-insertion mutation, as well as a control virus in which the insertion was repaired but which retained the multiple NRTI resistance mutations, was evaluated. The Michaelis-Menten constant (K m ) for datp and the inhibition constant (K i ) for TFV-PP of the wild-type and mutant RTs were determined. The excision of TFV from chainterminated primers and the effect of the next complementary nucleotide on this process by the wild-type and mutant enzymes were measured. Finally, computational models of the RT with the 69-insertion mutation complexed to TFV-PP and a model of the dinucleoside tetraphosphate excision product bound to the RT-primer-template complex were constructed and examined. MATERIALS AND METHODS Recombinant HIV-1 production and antiviral susceptibility assays. Fragments corresponding to the first 1,000 bp of HIV-1 RT were amplified from HIV-1 in plasma by PCR and cotransfected with HIV-1 proviral molecular clone phxb RT (a gift from C. Boucher, Utrecht University, Utrecht The Netherlands) from which the sequence for RT has been deleted, as described previously (2, 43). The replication-competent viruses were generated by homologous recombination and the genotypes were determined as described elsewhere (58). HIV-1 subtype B strain FS-SSS was obtained in 1997 from a patient who had undergone extensive antiretroviral treatment that included 5 years of monotherapy with AZT, followed by dual therapy with AZT and ddi and the subsequent addition of treatment with d4t, ddc, 3TC, protease inhibitors, and nonnucleoside RT inhibitors. The FS description of this virus is an arbitrary designation. The FS-SSS virus contained the following RT amino acid substitutions compared to the sequence of strain HXB2D: V35M, T39A, M41L, T69S, SS insertion, L74V, R83K, A98S, V108I, E122K, D123E, I135V, Q145C, D177E, G196E, T200A, L210W, R211K, L214F, T215Y, L228H, K249N, P272A, R277K, and E297K (the NRTI-associated resistance mutations are underlined). The FS virus was constructed from FS-SSS by site-directed mutagenesis and contained all of the substitutions described above except T69S, which was reverted to T69T, and the SS insertion was removed. The susceptibilities of the recombinant mutant viruses to TFV, ddi, abacavir, 3TC, ddc, d4t, and AZT were evaluated by the PhenoSense assay (ViroLogic,

3 994 WHITE ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 1. Polymerization diagram and ATP-mediated excision model. (A) RT polymerization cycle. RT binds to the template-primer (t/p n ) (step 1), in which the primer terminus resides in the P site and the N site is unoccupied. The incoming dntp binds to the N site (step 2). A rate-limiting conformational change occurs in step 3, in which the fingers subdomain moves from an open to a closed position (RT ). The phosphodiester bond formation occurs in step 4 to form the primer n 1, in which the primer terminus is in the N site and pyrophosphate (PPi) is produced and then released in step 5. After incorporation, the deoxynucleoside monophosphate (dnmp) is denoted n 1. This complex is also the substrate for the excision reaction shown in panel B. Translocation and an opening of the fingers domain occur before binding of the next dntp for the next round of polymerization. (B) Model of ATP-mediated excision. In this diagram, n 1 denotes the 3 terminus of the primer that may be an incorporated chain terminator and is the substrate for ATP-mediated excision. ATP binds to RT prior to translocation, when the terminal residue of the primer resides in the N site and the fingers are still in the closed position (step 7). The bound ATP forms a phosphodiester bond with the n 1 terminal primer to form dnmp-atp (step 8). In order for the dnmp-atp to be released, the RT fingers domain must undergo a putative conformational change to the open position (step 9). This is followed by the release of dnmp-atp, leaving the RT-template-primer n in the P site and an empty N site that it is available to bind to dntp for polymerization (step 10). The bottom row depicts the formation of the excision-resistant dead-end complex. For this reaction, the NRTI-terminated primer terminus resides in the P site. The 1 dntp binds (step 11), and this forms the salt-stable dead-end complex (step 12).

4 VOL. 48, 2004 MECHANISMS OF HIV RT RESISTANCE 995 Inc., South San Francisco, Calif.), which measures luciferase expression in a single-cycle replication assay in 293 cells (48). In this assay, the cutoff values for reduced susceptibility (fold change limits) to TFV, ddi, abacavir, 3TC, ddc, d4t, and AZT are 1.4, 1.7, 4.5, 2.5, 1.7, 1.7, and 2.5, respectively. For abacavir, ddi, d4t, and TFV, these susceptibility cutoff values are also the clinical cutoff values. The susceptibilities of FS-SSS, FS, and wild-type HIV-1 molecular clone HXB2D to TFV were also evaluated by a multiple-cycle 2,3-bis(2-methoxy-4-nitro-5- sulfophenyl)-2h-tetrazolium-5-carboxanilide (XTT)-based viability assay with MT-2 cells, as described previously (14). Recombinant RT construction, purification, and kinetic analyses. The wildtype RT expression construct prt66 (20) was a gift from M. Wainberg (McGill University, Montreal, Quebec, Canada). The pol sequences were amplified from the HXB2D molecular clone of HIV-1 or patient-derived viruses by PCR and cloned into the expression vector pkk223-3 (Amersham Pharmacia Biotech). The RT was expressed and purified from Escherichia coli strain JM109 as described previously (58). For all RT preparations, there were 80% p66/p66 homodimer and 20% p66/p51 heterodimer determined by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. The enzyme kinetic analyses were performed as described previously (44). The reaction mixtures for DNA-dependent DNA polymerase function contained 50 mm Tris-HCl (ph 7.8), 60 mm KCl, 10 mm MgCl 2, 5 mm dithiothreitol, 50 M each dntp, 150 g of activated calf thymus DNA (Amersham Pharmacia Biotech) per ml, and 30 to 100 Ci of the appropriate [ 3 H]dNTP (Amersham, Arlington Heights, Ill.) per mmol. Kinetic constants were determined by plotting the substrate concentration (S) versus the initial rate (v) data in a Michaelis-Menten hyperbolic relationship curve and fitting by nonlinear regression to the equation v V max S/(K m S) by using SigmaPlot (version 4.01) software. In these experiments, the template was present in excess, and competitive inhibition was observed on the basis of a constant V max when increasing concentrations of TFV-PP were assayed. ATP-mediated primer rescue assay. A 31-nucleotide (nt) DNA primer (primer L31; 5 -CTACTAGTTTTCTCCATCTAGACGATACCAG-3 ) (40) was 5 end labeled with [ - 33 P]ATP, annealed to a twofold excess of 50-nt DNA template WL50 (5 -GAGTGCTGAGGTCTTCATTCTGGTATCGTCTAGATGGAGA AAACTAGTAG-3 ) (39), and chain terminated with TFV-PP to produce a chain-terminated 32-mer. End-labeled, chain-terminated primers were gel purified twice on 8 M urea 16% polyacrylamide sequencing gels, excised, eluted in 0.5 M ammonium acetate 10 mm Tris-HCl (ph 7.5) 0.1 mm EDTA 2 mm MgCl % sodium dodecyl sulfate, and desalted by filtration through NAP10 columns (Amersham Pharmacia Biotech). Purified, chain-terminated primers were annealed to a fivefold excess of the WL50 DNA template. The chainterminated primer-template (2.5 nm) was incubated with RT enzyme in excess at approximately 30 nm wild-type recombinant RT enzyme or mutant enzymes in the presence of no complementary next nucleotide or increasing concentrations of the next nucleotide (final concentration, 0.1, 0.5, 2.5, 12.5, 62.5, or M) for 5 min at 37 C in RT removal buffer (50 mm Tris [ph 7.8], 60 mm KCl, 5 mm MgCl 2, 4.2% glycerol, 300 g of bovine serum albumin per ml), followed by the addition of ATP (3.2 mm final) or NaPP i (150 M final) to start the reaction. The reactions were stopped at 0.1, 5, 15, 30, and 45 min (ATP) or 0.1, 0.5, 1.5, 3, and 9 min (PP i ) by heat inactivation of RT at 90 C for 5 min, followed by placement on ice for 5 min. The unblocked primers were extended to full-length 50-mers through the addition of 500 M dntps and the Klenow fragment (exo ) ofe. coli DNA polymerase I (New England Biolabs, Beverly, Mass.) at 37 C for 30 min, as described previously (40). The reactions were stopped by the addition of an equivalent amount of formamide stop solution (U.S. Biochemicals, Cleveland, Ohio) at 30 min. The samples were heated at 95 C and run on 8 M urea 16% polyacrylamide sequencing gels, and the bands were quantified with a Storm 860 PhosphorImager (Amersham Pharmacia Biotech) and Image- Quant (version 5.0) software (Molecular Dynamics, Sunnyvale, Calif.). Degradation and extension of the primer band were less than 4% when each RT enzyme was incubated with the primer-template for 45 min at 37 C in the absence of ATP or PP i. Several control experiments were performed to confirm that the enzyme concentrations used were in excess of the primer-template concentration, that the RT enzyme was fully inactivated after the 5-min heat inactivation step, that the Klenow fragment enzyme was not capable of removing TFV from chain-terminated primers in the presence or absence of these concentrations of ATP, and that greater than 95% of the starting primers used were blocked by TFV (data not shown). The rate of excision (the percentage of TFV removed per minute) was determined by linear regression analysis of values in the linear range (0.1 to 45 min for wild-type RT, 0.1 to 15 min for SF-SSS RT, and 0.1 to 30 min for SF RT) by using SigmaPlot (version 4.01) software. The 50% inhibitory concentrations (IC 50 s) for the next complementary nucleotide on ATP-mediated excision were calculated as the means from three experiments. Statistical significance (P 0.05) was determined by two-tailed Student s t tests for the arrays of data. Molecular modeling. The structure of the ternary complex of HIV-1 RT, primer-template, and dttp of Huang et al. (25) was used as the starting point for all modeling studies. The model was converted into its corresponding minimized model by a force-field method (Sybyl molecular modeling software, version 6.8; Tripos Inc., St. Louis, Mo.). An iterative energy refinement protocol was applied to derive the final minimized RT structure (11, 12). These refinement methods have been used to produce modified models and homology models that have been successfully applied to prediction of the biological properties of proteins as well as to the discovery of inhibitor leads of therapeutic targets (8, 9, 11, 13). The predicted modified model representing the HIV-1 RT Ser69-Ser-Ser insertion-lys70 mutant was constructed by a loop search technique within Sybyl modeling software. Here, the wild-type K66-D67-S68-T69-K70 segment was replaced with the inserted K66-D67-S68-S69-S-S-K70 (mutant) segment taken from a library of known X-ray-determined loop structures in which K66 (wild type) and K70 (wild type) served as anchor positions. The final structure containing the insertion was constructed and minimized as described above. The original RT structure containing a dttp terminator nucleotide within the N site was removed and replaced with TFV-PP; in addition, the corresponding base group of the template strand was also modified to a pyrimidine in order to match the purine base of the inhibitor. The final step involved similar iterative minimization procedures, as described above. The RT-TFV-PP models were also converted to the RT-TFV-ATP models, which represented the product of ATP-mediated excision. First, the wild-type RT sequence was modified to include TAMs at positions 210 and 215. The modified side chain conformations of T215Y and L210W were placed such that both residues formed stable stacking interactions; these models were then minimized. Second, the phosphate group of AMP was joined to the beta phosphate of TFV-PP to form the TFV-ATP excision product. The AMP was then adjusted such that the purine base of AMP formed favorable stacking interactions with both T215Y and L210W. The final models of RT-TFV-ATP were energy minimized. A second modeling method, molecular dynamics (MD), was applied in order to study the movement of the RT active-site residues based on the conformational space of static X-ray structures (7, 21). Unlike energy minimization, in which the most energy-stable complex is depicted, the MD method is designed to include the effects of entropy and thus yields a model that represents the putative positions of residues in solution and that simulates the type of data obtained from nuclear magnetic resonance imaging determinations. MD is also used to determine potential conformational changes that can occur in proteins, such as solvent-exposed loop segments (10). Here, MD was used to determine the effect of the insertion in a T69S-SS L210W T215Y RT compared to that in a L210W- T215Y RT. Constrained MD simulations were carried out with both the wildtype and mutant RT-TFV-PP models. A 7-Å sphere around the TFV-ATP, including the complete loop region, was allowed to move during the molecular dynamics trajectories. The rest of the RT complex was energetically constrained to remain fixed to its original position. All simulations were carried out by the Tripos force-field method. The simulation system was heated from 0 to 300 K by using 50-degree increments. After system equilibration, the simulation was carried out for a total of 2 ns by using a 2-fs time step. The final 50 trajectories during the last 100 ps of the molecular dynamics run were averaged to derive the final three-dimensional model. RESULTS Patient-derived HIV-1 containing the 69-insertion mutation. HIV-1 isolates containing multiple TAMs and the 69-insertion mutation typically show high-level resistance to all NRTIs. To investigate the susceptibility to TFV of a virus containing these mutations, we selected a patient-derived virus containing a 69-insertion mutation obtained in 1997 from the baseline plasma sample from a closed clinical trial (27). Recombinant viruses were constructed from the RT sequence of the virus from this patient s plasma in an HIV-1 HXB2D background. The virus, labeled FS-SSS, contained multiple TAMs (M41L, L210W, T215Y) associated with reduced susceptibilities to NRTIs and TFV, the ddi and abacavir resistance mutation L74V, and the multinucleoside resistance insertion mutation

5 996 WHITE ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 2. Cell culture assays for drug susceptibility of the FS-SSS and FS viruses. (A) The fold changes in drug susceptibilities of mutant viruses FS-SSS (black bars) and FS (gray bars) compared to those of wild-type HIV-1 were determined by the PhenoSense assay (ViroLogic), and the values are indicated above the bars. The reduced susceptibility cutoffs for the drugs are indicated by horizontal lines and were 1.4, 1.7, 4.5, 2.5, 1.7, 1.7, and 2.5-fold for TFV, ddi, abacavir (ABC), 3TC, ddc, d4t, and AZT, respectively. For ABC, ddi, d4t, and TFV, these susceptibility cutoff values are also clinical cutoffs for a reduced response. (B) The fold changes in TFV susceptibilities of mutant viruses FS-SSS (black bars) and FS (gray bars) compared to those of the wild type were determined by using MT-2 cells, with the cytopathic effect quantified by a modified XTT-based assay. The fold change values are mean values from two to three experiments, with mean standard deviation fold change values shown. The 50% effective concentration of TFV for wild-type virus by this assay was 3.1 M. of T69S-SS, as well as several other substitutions (V35M, T39A, R83K, A98S, V108I, E122K, D123E, I135V, Q145C, D177E, G196E, T200A, R211K, L214F, L228H, K249N, P272A, R277K, E297K). A second virus, FS, was constructed from FS-SSS. In the virus FS, T69S-SS was reverted to T69 in order to address the specific role of the T69S substitution and insertion on the susceptibility of this virus to NRTIs. Susceptibility in cell culture. The cell-based antiviral drug susceptibilities of the FS-SSS and FS viruses were measured by the commercially available PhenoSense assay (Fig. 2A). The FS virus demonstrated high-level resistance to AZT (25-fold) and reduced susceptibilities that were near the cutoff values for clinical significance to TFV (1.5-fold), ddi (1.6-fold), d4t (1.8- fold), and 3TC (2.3-fold). The susceptibilities of FS to abacavir and ddc remained below the cutoff values of this assay. The FS-SSS virus showed more strongly reduced susceptibilities to all NRTIs: AZT, 1,160-fold; TFV, 4.8-fold; ddi, 3.0-fold; d4t, 7.7-fold; 3TC, 6.2-fold; abacavir, 13-fold; and ddc, 3.5- fold. The presence of the 69-insertion mutation contributed to a further 3.3-fold reduced TFV susceptibility of FS-SSS compared to that of FS. Susceptibility to TFV was also measured independently by an XTT-based assay with T lymphocytes. By this assay, the FS and FS-SSS viruses were 3.5- and 12.2-fold less susceptible, respectively, than the wild type (Fig. 2B). The second assay confirmed the decreased susceptibilities to TFV of viruses containing multiple TAMs and the further reduction in susceptibility to TFV in the presence of the 69-insertion mutation. The differences between the fold changes in drug susceptibility by these two assays may be explained by one or more differences between the assays, including the different cell types and the different reporter systems used and the single-round versus multiple-round assay lengths (14, 48). These viruses did not contain mutations associated with nonnucleoside RT or protease inhibitor resistance and remained susceptible to these drug classes (data not shown). Relative binding affinity measurements. One mechanism of resistance resulting from RT mutations is alteration of the binding or incorporation of the inhibitors with respect to that to their natural substrates (dntps). This mechanism allows the mutant RT to selectively discriminate between the NRTI and the natural substrate. Alterations in natural substrate and NRTI discrimination have been described for RTs with 69- insertion mutations (5, 33). We examined the abilities of the FS-SSS and FS RT enzymes to selectively bind to and incorporate datp, the natural substrate mimicked by TFV-PP, compared to their abilities to bind to and incorporate TFV-PP itself. The K m for datp, the K i for the active metabolite of TFV (TFV-PP), and the relative inhibitory capacity (K i /K m ratio) were measured for these mutants (Table 1). The K m value of wild-type RT for datp was 0.28 M and was consistent with the values presented in previous reports (19, 45, 58). The FS-SSS RT showed a slightly elevated K m value of 0.43 M for datp compared to that of wild-type RT (P 0.046). The K m of FS RT for datp was similar to that of wild-type RT (P 0.05). When the K i for TFV-PP was measured, FS-SSS RT yielded a K i value of 0.55 M, which was elevated 4.3-fold compared to the K i of 0.13 M of wild-type RT (P 0.01) (Table 1). The K i value of FS RT for TFV-PP was slightly increased to 0.26 M compared to that of the wild-type RT (P 0.05). The K i /K m ratio for TFV-PP was also calculated for the wild-type and mutant RT enzymes (Table 1). FS-SSS RT had a K i /K m ratio of TABLE 1. K m, K i, and K i /K m of wild-type and mutant HIV-1 RT enzymes a HIV-1 RT K m ( M) for datp K i ( M) TFV-PP K i /K m for TFV-PP/dATP Wild type (1.0) (1.0) 0.46 (1.0) FS-SSS b (1.5) c (4.3) 1.3 c (2.8) FS (1.3) b (2.0) 0.70 (1.5) a K m and K i values are the means standard deviations for four to eight experiments. Values in parentheses are the fold change from the value for the wild type. b P 0.05 compared to the wild type by two-tailed Student s t test. c P 0.01 compared to the wild type by two-tailed Student s t test.

6 VOL. 48, 2004 MECHANISMS OF HIV RT RESISTANCE , which was slightly, but significantly, increased 2.8-fold compared to that of the wild-type RT (P 0.01). The K i /K m ratio of FS RT was 0.7 and was only 1.5-fold increased over that of wild-type RT (P 0.09). We detected no differences in the K i and K m values of the wild-type RT enzyme preparation used in this study and those of a wild-type pure heterodimer RT (data not shown). The observed change in the level of discrimination by the FS-SSS RT, although statistically significant, was less than 3-fold, whereas the change in antiviral susceptibility by the MT-2 cell assay was 12.2-fold, suggesting that other resistance mechanisms may also be involved. Excision of chain terminators by the ATP-mediated excision mechanism. We analyzed the ATP-mediated excision of TFV in order to determine if this mechanism contributed to the susceptibility profiles of the FS and FS-SSS viruses. To measure excision, ATP was added at the physiological concentration of 3.2 mm (23, 56), in which it acts as a pyrophosphate donor to excise TFV from the primer terminus. In this assay, the excision step is followed by an extension reaction in the presence of all dntps to yield full-length primers. The mutant FS RT demonstrated significantly increased excision of TFV relative to that of the wild-type RT, and the FS-SSS insertion mutant showed the highest level of excision (Fig. 3). At 30 min, 24, 43, and 75% of the TFV was removed by the wild-type, FS, and FS-SSS RTs, respectively. For wild-type RT, we detected no differences in the levels of ATP-mediated excision for the enzyme preparation used in this study and a wild-type heterodimer RT (data not shown). When the rate of excision of this TFV-terminated primer-template by the mutated RT sequences was determined relative to that by the wild-type RT, the rate was increased 2.3-fold when multiple TAMs were present (FS RT) and was increased 4.5-fold with the addition of the 69-insertion mutation (FS-SSS RT). The excision of TFV by pyrophosphorolysis was also examined. The pyrophosphate-mediated excision by the wild-type enzyme was slightly more efficient than that by the mutant enzymes (data not shown). Effect of next complementary nucleotide on chain terminator excision. The effect of the next complementary nucleotide on TFV excision was determined (Fig. 4). In this assay, the next nucleotide (datp) efficiently inhibited the excision of TFV by wild-type RT, with an IC 50 of 1.2 M (Table 2). The IC 50 s for the next nucleotide for TFV excision were 4.6 and 14.1 M for the FS and FS-SSS RTs, respectively. This 12-fold increase in the IC 50 s for the next nucleotide for FS-SSS RT and the 4-fold increase in the IC 50 s for the next nucleotide for FS RT compared to the IC 50 for the next nucleotide for the wild-type RT suggests that the inhibitory effect of the next nucleotide on TFV excision is reduced by the insertion mutations compared to the effect of the RT whose sequence contains only background mutations. Although the dntp concentrations in replicating virion capsids in the cytoplasms of infected cells are not known, they vary by specific dntp in primary peripheral blood lymphocytes and are low in resting cells (0.3 to 5 M) but are increased when cells are activated (3 to 26 M) (17, 56). At a concentration of the next nucleotide (datp) of 5 M, a concentration observed in activated lymphocytes (17), the levels of TFV excision at 30 min were 5% for the wild-type RT and 17% for the FS RT (Table 2). However, for the FS-SSS RT, the FIG. 3. ATP-dependent excision of TFV chain-terminated primers by wild-type and mutant RTs. (A) A 5 end-labeled primer-template terminated with TFV was incubated with wild-type (WT), FS-SSS, or FS RT enzymes, followed by the addition of 3.2 mm ATP at 0.1, 5, 15, 30, and 45 min (indicated from left to right) at 37 C. The RT enzymes were heat inactivated, followed by the addition of dntps and the Klenow fragment to extend the unblocked primers to yield 50-nt fulllength products (extended primer). The reaction products were separated through 8 M urea 16% polyacrylamide sequencing gels and exposed to PhosphorImager screens. (B) The percentages of rescued primers over time were determined for the wild type (WT), FS-SSS, and FS and are means standard deviations from three experiments. level of excision remained high (59%), despite the presence of a putative physiological concentration of the next nucleotide. Molecular modeling of mutant HIV-1 RT. The molecular modeling studies were performed to visualize the interaction of the insertion mutation within the context of the enzyme-substrate complex and to aid in the generation of a hypothesis to describe the molecular mechanisms of resistance to TFV for this mutant. We modeled the wild-type and 69-insertion mutation RTs on the basis of the RT-DNA-dTTP crystal structure of Huang et al. (25). The models are shown in Fig. 5A and B, respectively. The ternary complexes of RT DNA TFV-PP (with TFV-PP binding to the N site) were examined. For this

7 998 WHITE ET AL. ANTIMICROB. AGENTS CHEMOTHER. complex, the placement of the insertion mutation in the fingers loop resulted in an elongated loop; however, the positions of the key binding sites (residues K65 and R72) of the incoming substrate (TFV-PP) were maintained (compare Fig. 5A and B). The energy-minimized models of wild-type and insertion mutant RTs suggest that the key active-site residues can reside in the positions defined in the crystal structure of Huang et al. (25). These models did not detect any steric conflict between TFV-PP and RT for either mutant, which is consistent with the lack of a large increase in the K i /K m ratio for this mutant. The energy-minimized models are not designed to depict the integrity or the entropy effects of these interactions. Therefore, MD models were created in which TFV-PP and the wild-type RT or the 69-insertion mutant RT dntp-binding site were allowed to undergo the conformational movements that may occur when this protein is present in solution. The results from these analyses are shown in Fig. 5C and D, respectively. In the wild-type RT model, TFV-PP displays only minimal movement in the dntp-binding pocket. The K65 and K66 side chain moieties remain stable (changes of 1.4 Å) and the D67 side FIG. 4. Effect of the next complementary nucleotide on the ATPdependent rescue of TFV chain-terminated primers. (A) Rescue of polymerization after excision of TFV by wild-type (WT), FS-SSS, and FS RTs in the presence of the next complementary nucleotide (datp) at 0, 0.1, 0.5, 2.5, 12.5, 62.5, and M. The excision reactions were initiated by the addition of 3.2 mm ATP for 30 min and heat inactivation of the RT, followed by the addition of 500 M dntps and the Klenow fragment for the extension reaction. (B) The percentages of rescued primers over time were determined for the wild type (WT), FS-SSS, and FS and are means standard deviations from three experiments. chain shows moderate movement of 3.6 Å from its location in the minimized structure. When the RT of the insertion mutant was examined, TFV-PP also showed minimal movement, as was seen with the wild-type RT. In contrast, the fingers loop of the 69-insertion mutant RT showed increased mobility relative to that of the wild-type RT, as illustrated by the increased movements of K65, K66, and D67 (2.6, 5.0, and 4.9 Å, respectively). This putative increase in mobility of the fingers-loop domain and movement away from the dntp may result in a decrease in the overall level of binding or the polymerization rate of the insertion RT compared to that of the wild-type RT and is in agreement with the subtle kinetic changes observed for this enzyme. The effect of the 69-insertion mutation on the ATP-mediated excision complex was also examined (Fig. 5E and F). The T215Y mutation appears to stack in rings with ATP to increase the affinity of RT for ATP, thus facilitating the excision process (3). The product of excision is a dinucleoside tetraphosphate (TFV-ATP, in the case of TFV). Energy-minimized and MD models were created to examine the excision complex consisting of an RT with the T69S-SS, L210W, and T215Y mutations (insertion) and an RT with only L210W and T215Y (210/215 RT) complexed with a DNA primer-template and the TFV-

8 VOL. 48, 2004 MECHANISMS OF HIV RT RESISTANCE 999 TABLE 2. Next nucleotide inhibition of ATP-mediated TFV excision by wild-type and mutant HIV-1 RT enzymes HIV-1 RT IC 50 ( M) for next nucleotide a ATP product of excision in the N site. These models depict the excision complex after the formation of the dinucleoside tetraphosphate and prior to its dissociation from the RT-primertemplate complex (between steps 8 and 9 of Fig. 1B). The energy-minimized models of the 210/215 and insertion RTs were similar overall. When the MD simulation was applied to the energy-minimized structure of RT bound to TFV-ATP, the fingers loop of the 69-insertion mutant RT had increased mobility compared to that of the 210/215 RT in these simulations. In addition, possibly due to the increased mobility of the fingers-loop domain, the TFV-ATP molecule was additionally observed to show displacement at the ATP moiety. The displacement of the ribose ring of ATP was increased to 5 Å by the 69-insertion mutant RT, whereas it was increased to 2 Å in the fingers-loop model of the wild-type RT. These models suggest that the increased mobility of the 3-4 loop of the 69-insertion mutant RT may facilitate the opening of the fingers-loop domain and the dissociation of the dinucleoside tetraphosphate from the RT-DNA complex and may decrease the level of formation or the stability of the next nucleotide-rt- DNA-TFV dead-end complex. DISCUSSION % TFV removed in 5 M next nucleotide b Wild type (1.0) c 5 (1.0) FS-SSS d (11.8) 59 (12) FS e (3.8) 17 (3.4) a IC 50 s were determined at 30 min and are the means standard deviations of three experiments. b Percentage of tenofovir removed at 30 min in 5 M datp. c Values in parentheses are the fold change from the value for the wild type. d P 0.01 compared to the value for the wild type by two-tailed Student s t test. e P 0.05 compared to the value for the wild type by two-tailed Student s t test. This study sought to describe the mechanisms of resistance of the 69-insertion mutant RT to TFV. The set of mutants described was particularly interesting because they also contained the M41L, L210W, and T215Y TAMs that are associated with decreased clinical responses to TDF (Miller et al., Program Abstr. Ninth Conf. Retrovir. Opportunistic Infect.). The addition of the diserine 69-insertion mutation was also of particular interest because it causes cross-resistance to all NRTIs and appears to use both mechanisms of resistance: decreased levels of binding or incorporation of dda, ddc, and 3TC (5) and increased levels of ATP-mediated excision of AZT, d4t, ddt, and dda (5, 30, 31, 33, 34, 37). However, these mechanisms do not appear to contribute equally to resistance for individual NRTIs. Decreased levels of binding and incorporation may contribute to resistance to ddi and 3TC, but the combination of the increased level of excision of NRTIs (AZT, d4t, dda, and ddc) from chain-terminated primers and the decreased level of inhibition of excision by the next nucleotide appears to be the major mechanism involved in resistance to NRTIs for 69-insertion mutants (5, 30, 31, 33, 34, 37). The presence of the 69-insertion mutation alone does not confer broad cross-resistance to NRTIs but requires the addition of TAMs for this multidrug resistance phenotype (29, 33). Boyer et al. (5) have shown, for example, that the 69-insertion mutation by itself had little effect on the excision of AZT from chain-terminated primers but, rather, enhanced the level of AZT excision when it was present with the TAM T215Y. In the present work, decreased levels of binding or incorporation of TFV by insertion mutant FS-SSS had a minor role in the observed resistance to TFV. Excision of chain terminators as a mechanism of resistance to AZT and, more recently, to d4t has been described as a second mechanism of resistance to NRTIs (1, 3, 30, 31, 38, 45, 46). The excision mechanism can be studied biochemically, in which a pyrophosphate donor (pyrophosphate or ATP) attacks the phosphodiester bond between the chain terminator and the previous nucleotide to release an unblocked primer terminus and an NRTI triphosphate or a dinucleoside tetraphosphate, respectively (Fig. 1B) (1, 3, 38). Several assays have been used to evaluate the role of the excision mechanism in resistance to the NRTI class of antiretroviral drugs. These excision assays have been quantified by examining either (i) the quantity of the remaining unblocked primer after excision of the chain terminator (1, 18, 33, 45, 46, 58), (ii) the direct products of excision (i.e., dinucleoside tetraphosphate) (37, 38, 40, 41), (iii) the appearance of the full-length extension products extended by either RT or other polymerases (18, 33, 34, 38 41), or (iv) the extension products after multiple rounds of incorporation and excision on homopolymeric or heteropolymeric templates (3 5, 30, 31, 38 40). TFV has been shown to be excised by wild-type RT from DNA annealed to an HIV RNA template in the presence of pyrophosphate, but excision was barely detectable when ATP was used as the pyrophosphate donor (45, 46, 58). In the present study we used the third method of analyzing the excision of TFV from DNA annealed to an HIV-1 DNA template using ATP as the pyrophosphate donor. Higher levels of excision of TFV by wild-type RT was measured by this assay than by previous assays, and the level was further increased by the mutant RTs studied. The differences in excision rates between these studies may be due to differences in the specific primer-template analyzed, the use of DNA versus RNA templates, the assay methodology, and/or the effects of the different RT mutations analyzed. The present study used RT enzymes containing TAMs M41L, L210W, and T215Y, whereas the previous studies of AZT-resistant RT lacked the M41L and L210W mutations (45, 46). Thus, in addition to TAMs that result in increased levels of excision of AZT, d4t, ddi, and abacavir (3, 5, 18, 38 41, 45, 46, 50), increased levels of excision of TFV can also be demonstrated with the pattern of TAMs used in the present study. The 69-insertion mutation further increased the level of excision of TFV, which was also consistent with the data for AZT, d4t, and ddi (5, 33, 34, 37). However, excision must be considered in the context of the physiologically relevant next nucleotide concentrations present in cells. The next complementary nucleotide and the chain-terminated primer-template-rt complex can form a salt-stable dead-end complex that is resistant to chain-terminator excision (38, 39, 55). When dntp concentrations are low, the rate of excision may be increased due to the lower level of inhibition

9 1000 WHITE ET AL. ANTIMICROB. AGENTS CHEMOTHER. by the next complementary nucleotide. The inhibition of excision by the next nucleotide likely occurs after translocation of the chain terminator from the N site to the P site, and dntp binds at the N site (3, 52). This hypothesis is supported by several pieces of data, which can be summarized by comparison of the excisions of AZT and d4t. AZT is thought to reside primarily in the N site because the azido group interacts unfavorably with the active-site aspartic acid residues when it is modeled or retained at the P site in a crystal structure (3, 52). d4t, on the other hand, is not expected to show this steric conflict and should translocate efficiently to the P site (3, 46). AZT and d4t are removed efficiently by ATP, but higher levels of the next nucleotide are required for AZT than for d4t to achieve an inhibitory effect on excision. For TFV, only low levels of the next nucleotide ( 1 M datp) were required for inhibition of excision by wild-type RT. This inhibition required higher levels of the next nucleotide for RT containing multiple TAMs and even higher levels with the addition of the 69- insertion mutations. Similar observations have been made for TAMs and 69-insertion mutations with other NRTIs, such as dda and AZT (5, 33, 34, 40). Because dntp levels in cells can vary substantially between different cell types and during the cell cycle (56), cells with low dntp concentrations would show increased levels of ATP-mediated excision as a result of the decreased levels of inhibition by the next nucleotide. As discussed in previous reports on this topic (34, 37), the dntp concentrations in cells can vary greatly; however, for activated lymphocytes in vivo, this value lies in the low micromolar range (17). Although the dntp concentrations in virion capsids undergoing reverse transcription in the cytoplasms of infected cells are not known, at concentrations ranging over 3 logs around the observed intracellular concentration, the rates of excision of TFV were low for the wild-type RT and moderate for the FS mutant RT containing multiple TAMs; the rate was efficient for the FS-SSS RT containing the 69-insertion mutation compared to that for the wild-type RT. The 69-insertion mutation is located in the 3-4 loop of the fingers domain of RT and contains residues that make important contacts between the incoming nucleotide and the RT active site. We hypothesized that the insertion in the FS-SSS RT created a larger solvent-exposed loop and, hence, should have greater flexibility or mobility, supporting the hypotheses of others (54). The MD models presented here further support this hypothesis. The proposed increased mobility of the fingers loop conferred by the 69-insertion mutations may influence the binding of the next complementary nucleotide or the stability of the ternary complex, as observed here and by others (5, 33, 34, 37). Our results further suggest that that the increased FIG. 5. Molecular models of HIV-1 RT bound to TFV-PP and TFV-ATP. (A and B) The energy-minimized models of TFV-PP bound to wild-type RT (A) and T69S-SS RT (B) are shown. Residues important in stabilizing this complex are labeled and include K65, K66, K70, and R72. The minimized models show that the insertion does not directly break any critical interactions. The inserted segment occurs at the end of the finger loop and is solvent exposed. (C and D) MDaveraged molecular models of RT bound to TFV-PP are shown for the wild-type RT (C) and the T69S-SS RT (D). The energy-minimized models are colored blue, and the dynamics-averaged structures are shown in atom-type colors. The distances shown as dashed lines indicate the deviations of the polar functional groups between the minimized (MIN) and dynamic (DYN) structures. For wild-type RT, the distances were modest: K65, 1.4 Å; K66, 1.2 Å; and D67, 3.6 Å. These distances were increased for the 69-insertion mutant RT structure: K65, 2.6 Å; K66, 5.0 Å; and D67, 4.9 Å. (E and F) The energyminimized models (blue) and MD-averaged models (atom-type colors) of the TFV-ATP excision product complexed to L210W-T215Y RT (E) or T69S-SS L210W T215Y RT (F) are shown. The insertion does not directly break any critical interactions. The distance measured indicates the deviations of the cyclic ribose ring between the minimized and dynamic models. The dynamics-averaged models show a larger movement of the ribose ring for the insertion-containing structure (5.0 Å) than for the structure without the insertion (2.0 Å).

Management of NRTI Resistance

Management of NRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington

More information

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action

More information

Anumber of clinical trials have demonstrated

Anumber of clinical trials have demonstrated IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines

More information

172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.

172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2. 5 5 5 5 A MgCl 2 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] B 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] ATP + ATP - Supplemental Figure 1. Primer extension of HIV-1 RT polymorphisms

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

Because accurate and reproducible phenotypic susceptibility

Because accurate and reproducible phenotypic susceptibility BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and

More information

Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance?

Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance? Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance? Paul L. Boyer 1, Stefan G. Sarafianos 2, Patrick K. Clark 3, Eddy Arnold 2, Stephen H. Hughes 1* 1 HIV Drug Resistance Program,

More information

Evaluation and Management of Virologic Failure

Evaluation and Management of Virologic Failure National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:

More information

Antiviral Therapy 6:

Antiviral Therapy 6: Antiviral Therapy 6: 115-127 Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator

More information

Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients

Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients JAIDS Journal of Acquired Immune Deficiency Syndromes 31:121 127 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communications Subtle Decreases in Stavudine Phenotypic Susceptibility Predict

More information

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine Journal of Antimicrobial Chemotherapy Advance Access published December 9, 2009 J Antimicrob Chemother doi:10.1093/jac/dkp422 esistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

More information

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase Viruses 2010, 2, 606-638; doi:10.3390/v2020606 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase

More information

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f. Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve

More information

NIH Public Access Author Manuscript Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 June 15.

NIH Public Access Author Manuscript Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 June 15. NIH Public Access Author Manuscript Published in final edited form as: Bioorg Med Chem Lett. 2012 June 15; 22(12): 4064 4067. doi:10.1016/j.bmcl.2012.04.078. Pre-steady state kinetic analysis of cyclobutyl

More information

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine

More information

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter

More information

Viral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles

Viral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles Viral Resistance with Topical RT-Microbicides Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles verview What antiretrovirals (ARV) are being considered as candidate microbicides? How

More information

Received 21 April 2005/Accepted 21 June 2005

Received 21 April 2005/Accepted 21 June 2005 JOURNAL OF VIROLOGY, Sept. 2005, p. 12045 12057 Vol. 79, No. 18 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.18.12045 12057.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Human

More information

PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES

PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,

More information

Betancor et al. Retrovirology 2012, 9:68

Betancor et al. Retrovirology 2012, 9:68 Betancor et al. Retrovirology 2012, 9:68 RESEARCH Open Access Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue

More information

Somnuek Sungkanuparph, M.D.

Somnuek Sungkanuparph, M.D. HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor

More information

Antiviral Chemotherapy

Antiviral Chemotherapy Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus

More information

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016

More information

The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites

The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites Journal of Antimicrobial Chemotherapy Advance Access published June 7, 2013 J Antimicrob Chemother doi:10.1093/jac/dkt204 The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide

More information

Life Sciences 1A Midterm Exam 2. November 13, 2006

Life Sciences 1A Midterm Exam 2. November 13, 2006 Name: TF: Section Time Life Sciences 1A Midterm Exam 2 November 13, 2006 Please write legibly in the space provided below each question. You may not use calculators on this exam. We prefer that you use

More information

Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors

Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors JOURNAL OF VIROLOGY, July 2006, p. 7186 7198 Vol. 80, No. 14 0022-538X/06/$08.00 0 doi:10.1128/jvi.02084-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Involvement of Novel

More information

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay

modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes

More information

The E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays

The E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays AAC Accepts, published online ahead of print on 13 January 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02114-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 The E138A

More information

Resistance Workshop. 3rd European HIV Drug

Resistance Workshop. 3rd European HIV Drug 3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance

More information

7.014 Problem Set 7 Solutions

7.014 Problem Set 7 Solutions MIT Department of Biology 7.014 Introductory Biology, Spring 2005 7.014 Problem Set 7 Solutions Question 1 Part A Antigen binding site Antigen binding site Variable region Light chain Light chain Variable

More information

Molecular Mechanisms by Which Human Immunodeficiency Virus Type 1 Integrase Stimulates the Early Steps of Reverse Transcription

Molecular Mechanisms by Which Human Immunodeficiency Virus Type 1 Integrase Stimulates the Early Steps of Reverse Transcription JOURNAL OF VIROLOGY, Sept. 2007, p. 10037 10046 Vol. 81, No. 18 0022-538X/07/$08.00 0 doi:10.1128/jvi.00519-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Molecular Mechanisms

More information

Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania

Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania International Journal of Infectious Diseases (2009) 13, 81 89 http://intl.elsevierhealth.com/journals/ijid Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated

More information

Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure

Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2010, p. 4799 4811 Vol. 54, No. 11 0066-4804/10/$12.00 doi:10.1128/aac.00716-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Mechanisms

More information

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against

More information

History (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11

History (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11 (August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,

More information

HIV-1 infection has been the target of various multidrug therapies,

HIV-1 infection has been the target of various multidrug therapies, HIV-1 and HIV-2 Reverse Transcriptases: Different Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors Paul L. Boyer, a Patrick K. Clark, b and Stephen H. Hughes a HIV Drug Resistance

More information

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness CLINICAL MICROBIOLOGY REVIEWS, Oct. 2007, p. 550 578 Vol. 20, No. 4 0893-8512/07/$08.00 0 doi:10.1128/cmr.00017-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Clinical Significance

More information

To test the possible source of the HBV infection outside the study family, we searched the Genbank

To test the possible source of the HBV infection outside the study family, we searched the Genbank Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),

More information

Broad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates

Broad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates MAJOR ARTICLE Broad Nucleoside Reverse-Transcriptase Inhibitor Cross-Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates Jeannette M. Whitcomb, Neil T. Parkin, Colombe Chappey, Nicholas

More information

Antivirals. Lecture 20 Biology 3310/4310 Virology Spring 2017

Antivirals. Lecture 20 Biology 3310/4310 Virology Spring 2017 Antivirals Lecture 20 Biology 3310/4310 Virology Spring 2017 You can t go back and you can t stand still. If the thunder don t get you, then the lightning will. JERRY GARCIA The Wheel (lyrics by Robert

More information

Zalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15

Zalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15 Zalcitabine 2-3 -dideoxycytidine, ddc TUD DaMocles SoSe 15 Nina Drechsler, Christoph Drexler, Robin Dursun, Malte Eckert Graphic 1: Zalcitabine Table of Contents Content 1.... Introduction 1 2.... Properties

More information

7.012 Quiz 3 Answers

7.012 Quiz 3 Answers MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Friday 11/12/04 7.012 Quiz 3 Answers A > 85 B 72-84

More information

Human Immunodeficiency Virus Type 2 Reverse Transcriptase Activity in Model Systems That Mimic Steps in Reverse Transcription

Human Immunodeficiency Virus Type 2 Reverse Transcriptase Activity in Model Systems That Mimic Steps in Reverse Transcription JOURNAL OF VIROLOGY, July 2003, p. 7623 7634 Vol. 77, No. 13 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.13.7623 7634.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Human Immunodeficiency

More information

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.

More information

Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir

Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2007, p. 2911 2919 Vol. 51, No. 8 0066-4804/07/$08.00 0 doi:10.1128/aac.00314-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Effects

More information

Tenofovir Resistance and Resensitization

Tenofovir Resistance and Resensitization ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2003, p. 3478 3484 Vol. 47, No. 11 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.11.3478 3484.2003 Copyright 2003, American Society for Microbiology. All Rights

More information

HIV - Life cycle. HIV Life Cyle

HIV - Life cycle. HIV Life Cyle Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic

More information

Clinical Management of HIV Drug Resistance

Clinical Management of HIV Drug Resistance Viruses 2011, 3, 347-378; doi:10.3390/v3040347 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Clinical Management of HIV Drug Resistance Karoll J. Cortez and Frank Maldarelli *

More information

MedChem 401~ Retroviridae. Retroviridae

MedChem 401~ Retroviridae. Retroviridae MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The

More information

Template Dimerization Promotes an Acceptor Invasion-Induced Transfer Mechanism during Human Immunodeficiency Virus Type 1 Minus-Strand Synthesis

Template Dimerization Promotes an Acceptor Invasion-Induced Transfer Mechanism during Human Immunodeficiency Virus Type 1 Minus-Strand Synthesis JOURNAL OF VIROLOGY, Apr. 2003, p. 4710 4721 Vol. 77, No. 8 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.8.4710 4721.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Template Dimerization

More information

Section 6. Junaid Malek, M.D.

Section 6. Junaid Malek, M.D. Section 6 Junaid Malek, M.D. The Golgi and gp160 gp160 transported from ER to the Golgi in coated vesicles These coated vesicles fuse to the cis portion of the Golgi and deposit their cargo in the cisternae

More information

Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)

Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,

More information

Department of Microbiology, School of Medicine, Box , University of Washington, Seattle, WA 98195, USA

Department of Microbiology, School of Medicine, Box , University of Washington, Seattle, WA 98195, USA Virology 366 (2007) 361 376 www.elsevier.com/locate/yviro Substitution of alanine for tyrosine-64 in the fingers subdomain of M-MuLV reverse transcriptase impairs strand displacement synthesis and blocks

More information

Antiviral Therapy 2011; 16: (doi: /IMP1851)

Antiviral Therapy 2011; 16: (doi: /IMP1851) Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure

More information

Lecture 34. Carbohydrate Metabolism 2. Glycogen. Key Concepts. Biochemistry and regulation of glycogen degradation

Lecture 34. Carbohydrate Metabolism 2. Glycogen. Key Concepts. Biochemistry and regulation of glycogen degradation Lecture 34 Carbohydrate Metabolism 2 Glycogen Key Concepts Overview of Glycogen Metabolism Biochemistry and regulation of glycogen degradation Biochemistry and regulation of glycogen synthesis What mechanisms

More information

To date, 33 million people worldwide are infected with

To date, 33 million people worldwide are infected with HIV- reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision Krista A. Delviks-Frankenberry, Galina N. Nikolenko, Paul L. oyer, Stephen H. Hughes,

More information

Tala Saleh. Ahmad Attari. Mamoun Ahram

Tala Saleh. Ahmad Attari. Mamoun Ahram 23 Tala Saleh Ahmad Attari Minna Mushtaha Mamoun Ahram In the previous lecture, we discussed the mechanisms of regulating enzymes through inhibitors. Now, we will start this lecture by discussing regulation

More information

Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen

Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**

More information

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL SUPPLEMENTARY MATERIAL Purification and biochemical properties of SDS-stable low molecular weight alkaline serine protease from Citrullus Colocynthis Muhammad Bashir Khan, 1,3 Hidayatullah khan, 2 Muhammad

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:

More information

Supplementary materials

Supplementary materials Supplementary materials Chemical library from ChemBridge 50,240 structurally diverse small molecule compounds dissolved in DMSO Hits Controls: No virus added μ Primary screening at 20 g/ml of compounds

More information

HIV Drug Resistance: An Overview

HIV Drug Resistance: An Overview Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral

More information

Resistance to Integrase Strand Transfer Inhibitors

Resistance to Integrase Strand Transfer Inhibitors NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases

More information

The MOLECULES of LIFE

The MOLECULES of LIFE The MOLECULES of LIFE Physical and Chemical Principles Solutions Manual Prepared by James Fraser and Samuel Leachman Chapter 16 Principles of Enzyme Catalysis Problems True/False and Multiple Choice 1.

More information

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European

More information

Emerging CMV Resistance Profile for CMX001

Emerging CMV Resistance Profile for CMX001 Emerging CMV Resistance Profile for CMX001 International Conference on Antiviral Research May 15, 2013 Randall Lanier, PhD Forward Looking Statements These slides and the accompanying oral presentation

More information

Resistance of Human Cytomegalovirus to Antiviral Drugs

Resistance of Human Cytomegalovirus to Antiviral Drugs CLINICAL MICROBIOLOGY REVIEWS, Apr. 1999, p. 286 297 Vol. 12, No. 2 0893-8512/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Resistance of Human Cytomegalovirus to

More information

Signal Transduction Cascades

Signal Transduction Cascades Signal Transduction Cascades Contents of this page: Kinases & phosphatases Protein Kinase A (camp-dependent protein kinase) G-protein signal cascade Structure of G-proteins Small GTP-binding proteins,

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 Asymmetrical function of 5p and 3p arms of mir-181 and mir-30 families and mir-142 and mir-154. (a) Control experiments using mirna sensor vector and empty pri-mirna overexpression

More information

HIV replication and selection of resistance: basic principles

HIV replication and selection of resistance: basic principles HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS

More information

A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors

A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors JOURNAL OF VIROLOGY, May 2010, p. 5238 5249 Vol. 84, No. 10 0022-538X/10/$12.00 doi:10.1128/jvi.01545-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. A Novel Molecular Mechanism

More information

Title. HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in

Title. HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Title HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance October 13, 2004 Authors SY Rhee

More information

Les thérapeutiques antirétrovirales : entre nouveauté et expérience

Les thérapeutiques antirétrovirales : entre nouveauté et expérience Les thérapeutiques antirétrovirales : entre nouveauté et expérience Les nouveaux ARV, un réel besoin virologique Aix en Provence, 2018 JC Tardy, Lyon New antiretroviral agent use affects prevalence of

More information

Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review

Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department

More information

Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation

Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation J. Du 1, Z.H. Tao 2, J. Li 2, Y.K. Liu 3 and L. Gan 2 1 Department of Chemistry,

More information

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for

More information

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1 Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,

More information

Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase

Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase JOURNAL OF VIROLOGY, June 2004, p. 6112 6121 Vol. 78, No. 12 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.12.6112 6121.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Characterization

More information

Previous Class. Today. Detection of enzymatic intermediates: Protein tyrosine phosphatase mechanism. Protein Kinase Catalytic Properties

Previous Class. Today. Detection of enzymatic intermediates: Protein tyrosine phosphatase mechanism. Protein Kinase Catalytic Properties Previous Class Detection of enzymatic intermediates: Protein tyrosine phosphatase mechanism Today Protein Kinase Catalytic Properties Protein Phosphorylation Phosphorylation: key protein modification

More information

ICAAC/IDSA DC, Oct. 26, 2008

ICAAC/IDSA DC, Oct. 26, 2008 Tenofovir (TDF)- or Abacavir (ABC)-selected Minority Subpopulations in Viremic Subjects Detected by Ultra-deep Sequencing R. T. D Aquila 1, E. Rouse 2, J. Horton 2, A. Kheshti 1,3, S. Raffanti 1,3, K.

More information

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded

More information

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC

More information

DIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:

DIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA: Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):

More information

Supplementary information

Supplementary information Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc

More information

Supplementary Figure 1 Weight and body temperature of ferrets inoculated with

Supplementary Figure 1 Weight and body temperature of ferrets inoculated with Supplementary Figure 1 Weight and body temperature of ferrets inoculated with A/Anhui/1/2013 (H7N9) influenza virus. (a) Body temperature and (b) weight change of ferrets after intranasal inoculation with

More information

Supplementary Information

Supplementary Information Supplementary Information HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids Authors: Pei-Yi Su 1,2,3, Ching-Jen Yang 2, Tien-Hua Chu

More information

Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab

Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab Monitoring for Drug Resistance by Genotyping Urvi M Parikh, PhD MTN Virology Core Lab Outline What is Drug Resistance? Genotyping Algorithm Standard vs Sensitive Resistance Testing Sequencing Protocols

More information

Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh

Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these

More information

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Review Antiviral Therapy 10:13 28 Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection Mark A Wainberg 1 *, James PC Sawyer 2, Julio SG Montaner

More information

List of Figures. List of Tables

List of Figures. List of Tables Supporting Information for: Signaling Domain of Sonic Hedgehog as Cannibalistic Calcium-Regulated Zinc-Peptidase Rocio Rebollido-Rios 1, Shyam Bandari 3, Christoph Wilms 1, Stanislav Jakuschev 1, Andrea

More information

DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone

DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood

More information

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017 Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for

More information

MECHANISMS BY WHICH NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BLOCK HIV-1 REPLICATION ALONE AND IN COMBINATION WITH

MECHANISMS BY WHICH NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BLOCK HIV-1 REPLICATION ALONE AND IN COMBINATION WITH MECHANISMS BY WHICH NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BLOCK HIV-1 REPLICATION ALONE AND IN COMBINATION WITH OTHER REVERSE TRANSCRIPTASE INHIBITORS by Jessica Ann Radzio BS, Virginia Polytechnic

More information

Introduction to the Impact of Resistance in Hepatitis C

Introduction to the Impact of Resistance in Hepatitis C Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored

More information

Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail

Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail HAART, HIV correlated pathologies and other infections Renato Maserati Differentiating emtricitabine (FTC) from lamivudine (3TC): what a fine-tuning of antiretroviral therapy might entail Corresponding

More information

Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,

Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

L I F E S C I E N C E S

L I F E S C I E N C E S 1a L I F E S C I E N C E S 5 -UUA AUA UUC GAA AGC UGC AUC GAA AAC UGU GAA UCA-3 5 -TTA ATA TTC GAA AGC TGC ATC GAA AAC TGT GAA TCA-3 3 -AAT TAT AAG CTT TCG ACG TAG CTT TTG ACA CTT AGT-5 OCTOBER 31, 2006

More information